Dr. Lore Gruenbaum joined LLS in 2020 as the Vice President for the Therapy Acceleration Program (TAP), the LLS venture philanthropy program aiming to accelerate high-risk, innovative blood cancer therapeutics. She brings 20 years of drug discovery and clinical development experience to LLS working on small molecules, biologics, RNA-directed and cell therapies in multiple therapeutic areas including oncology, immunology, virology and neuroscience. Most recently, Dr. Gruenbaum was employed as the Vice President, Biology at Gotham Therapeutics pioneering drug discovery in Epitranscriptomics. Prior to this, she was part of the executive leadership team at Applied Biomath where she led collaborative mechanistic modeling projects to accelerate and de-risk drug development for biotech and pharma and acted as the principal investigator on a NIH small business grant. Dr. Gruenbaum held roles of increasing responsibility at Boehringer Ingelheim and Roche Pharmaceuticals driving technical innovation, predictive toxicology, novel mechanistic and biomarker strategies for drug discovery and clinical projects. She completed her Ph.D. at Free University of Berlin with ‘summa cum laude’ and conducted postdoctoral studies at Yale University.